Results 281 to 290 of about 299,030 (338)

Translation, cross-cultural adaptation, and validation of the Integrated Palliative Care Outcome Scale Renal (IPOS-Renal) for Brazilian Portuguese. [PDF]

J Bras Nefrol
Trindade MAD, Figueiredo AEPL, Poli-de-Figueiredo CE.   +2 more
europepmc   +1 more source

Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoadsorption – A prospective monocenter pilot study

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Bullous pemphigoid (BP) is the most common autoimmune blistering disease in the Western world. While remission is achieved in the majority of BP patients by long‐term use of corticosteroids with or without immunomodulants/immunosuppressants, national and international guidelines recommend adjuvant immunoadsorption (IA)
Maike M. Holtsche, Nina van Beek, Christoph M. Hammers, Artem Vorobyev, Michael Kasperkiewicz, Nina Schumacher, Philip Muck, Enno Schmidt   +7 more
wiley   +1 more source

Obesity and Its Clinical Implications in End-Stage Kidney Disease. [PDF]

Medicina (Kaunas)
Petruliene K, Zilinskiene A, Vaiciuniene R, Vaiciunas K, Bumblyte IA, Dalinkeviciene E.   +5 more
europepmc   +1 more source

Progression of albumin/creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR) over 24 years in people with type 2 diabetes. Drivers, potential protectors and associated mortality

Diabetic Medicine, EarlyView.
Abstract Introduction The pathophysiology of chronic kidney disease (CKD) and type 2 diabetes (T2D) is multifactorial and associated with a plethora of underlying conditions and complications. Their link is reciprocal and understanding its nature, particularly over time, could improve the health of many.
Andreas Matheou, Orestis Zavlis, Steve White, Thomas McDonnell, Alexander Warner‐Levy, John Warner‐Levy, Loren Wilkins, Hellena Habte‐Asres, Abigail Lay, Liliana Shalamanova, Martin Whyte, Martin Gibson, Philip A. Kalra, Adrian Heald   +13 more
wiley   +1 more source

Efficacy of belimumab on extra-renal lupus in patients with lupus nephritis and end-stage renal disease. [PDF]

Front Med (Lausanne)
Teng JQ, Guo WP, Xu J, Tan M, Tan Y, Qu Z, Su HH, Yu F.   +7 more
europepmc   +1 more source

Literature‐informed ensemble machine learning for three‐year diabetic kidney disease risk prediction in type 2 diabetes: Development, validation, and deployment of the PSMMC NephraRisk model

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Introduction Diabetic kidney disease (DKD) and diabetic nephropathy (DN) affect around 40% of diabetic patients but lack accurate risk prediction tools that include social determinants and demographic complexity. We developed and validated an ensemble machine learning model for three‐year DKD/DN risk prediction with deployment readiness ...
Ayla M. Tourkmani, Turki J. Al‐Harbi, Ahmad Abdullah Alghamdi, Ibrahim M. Youzghadli, Faris Saad Alosaimi, Ahmed Y. Azzam   +5 more
wiley   +1 more source

The Spectrum of Motor Disorders in Patients with Chronic Kidney Disease: Pathogenic Mechanisms, Clinical Manifestations, and Therapeutic Strategies. [PDF]

J Clin Med
Jerzak P, Mizera J, Gołębiowski T, Kuriata-Kordek M, Banasik M.   +4 more
europepmc   +1 more source

Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim This study evaluated the efficacy and safety of empagliflozin 10 and 25 mg compared to placebo as add‐on treatment for people with type 2 diabetes mellitus (T2DM) uncontrolled after ≥8 weeks of treatment with metformin and sitagliptin. Materials and Methods A randomised, double‐blind, multicentre, therapeutic confirmatory, phase 3 clinical
Seung‐Hwan Lee, Kyung Ah Han, Eun‐Gyoung Hong, Jun Goo Kang, Choon Hee Chung, Jong Chul Won, Eon Ju Jeon, Jung‐Hwan Cho, Ho Chan Cho, Sin Gon Kim, Eun Seok Kang, So Hun Kim, Hae Jin Kim, In‐Kyung Jeong, Sung Wan Chun, Young Min Cho   +15 more
wiley   +1 more source

Cefiderocol Elimination During Peritoneal Dialysis: A Short Report. [PDF]

Cureus
Müller-Kühnle J, Rittershofer B, Schanz M, Allgäuer S, Muerdter T, Schricker S.   +5 more
europepmc   +1 more source

Determinants of circulating PCSK9 levels and the efficacy of PCSK9 inhibitor therapies in chronic kidney disease: a systematic review. [PDF]

Eur J Clin Pharmacol
Ábel T, Benczúr B, Csajbókné ÉC.
europepmc   +1 more source